PASG Passage BIO, Inc. Insider Trading

10% owner Lynx1 Capital buys 32,008 shares at $6.99 blended avg across 3 purchases Sept 11–15.

Lynx1 Capital Management LP, holding 623.7K shares post-transaction (a 5.4% increase from prior holdings of 591.7K shares), executed 3 separate purchases totaling 32,008 shares for $223,734.69 at a blended average price of $6.99 on September 11, 12, and 15, 2025. At the time of purchase, the stock was trading near this price level and currently sits at $6.95, only 0.6% below the blended transaction price—indicating the purchases were not at a valuation extreme. Lynx1's historical track record at PASG shows strong outcomes: 2 of 2 prior buys with measurable 90-day results yielded +1778.8% and +1858.0% returns, and the 3 most recent July purchases showed 30-day returns of +32.0%, +31.3%, and +36.1%. However, the company's fundamentals are materially weak—net income of $-9,385,000.00 and a market cap of only $22,092,034.50—rendering the firm unprofitable at the full-year level and raising questions about the sustainability of prior outsized gains.

10% owner Lynx1 Capital bought 128,848 shares across 3 days ($733.8K) at $5.70 avg, extending holding to 591.7K post-transaction.

Lynx1 Capital Management LP, a 10% shareholder, executed 3 separate purchases totaling 128,848 shares for $733,825.53 between July 22–24, 2025, expanding its position by 27.8%. This significant expansion occurs while the stock trades 74.6% below its 52-week high of $22.60 and down 18.5% over the prior 30 days, amid a backdrop of trailing-twelve-month net income of $-15,405,000 (unprofitable). Notably, across Lynx1's 4 prior trades at PASG (all buys in Nov–Dec 2024), all exhibited positive 90-day returns ranging from +1181.0% to +1760.7%, indicating a consistent pattern of well-timed entry points at this specific ticker. The current filing represents a material accumulation that warrants monitoring given both the insider's track record at this ticker and the company's ongoing unprofitability.

10% Owner Lynx1 Capital bought 373,645 shares of PASG at $0.65 on 2024-12-27; stock down 67.2% from 52-week high.

Lynx1 Capital purchased 373,645 shares at $0.65, expanding its stake from 8,883,308 to 9,256,953 shares—a modest 4.2% increase in holdings. This is the insider's fourth discrete buy at PASG within a 32-day window (late November through late December 2024), following three prior purchases on 2024-11-25, 2024-11-26, and 2024-11-27. The current stock price of $11.34 reflects a 67.2% decline from the 52-week high of $34.60 and a 49.8% drop over the past 30 days, establishing a sharply depressed near-term backdrop. However, the company reported negative net income of $-19,340,000.00 over its most recent full fiscal year, indicating ongoing losses that warrant scrutiny of whether repeated accumulation at declining prices reflects fundamental conviction or simply mechanical execution of a planned capital deployment in an unprofitable business experiencing severe recent downward momentum.

10% owner Lynx1 Capital buys 456,353 shares across 3 transactions for $284,519.51; holdings rise to 8.88M

Lynx1 Capital Management LP, a 10% owner of Passage BIO, executed three separate open-market purchases totaling 456,353 shares (456.4K shares) between November 25–27, 2024 at prices ranging from $0.56 to $0.71, with a blended average of $0.62. This represents a 5.4% increase to the investor's holdings, bringing them to 8.88M shares post-transaction. The purchases occurred while the stock trades at $13.33, approximately 61.5% below its 52-week high of $34.60, suggesting the accumulation took place during a significant pullback. The company remains unprofitable with net income of $-19.3M over its most recent full fiscal year, and the insider's cross-ticker track record shows only 1 prior buy, limiting the ability to contextualize this action against an established pattern of conviction or opportunistic buying.